Osimertinib Plus Chemo Confirmed as First-Line Standard in EGFR-Mutant NSCLC
Author summary: Osimertinib plus chemo is the new standard.
Adding chemotherapy to first-line treatment with osimertinib can improve overall survival (OS) in patients with EGFR-mutant, advanced non-small cell lung cancer (NSCLC), according to results from the FLAURA2 trial.
“These compelling overall survival results from the FLAURA2 trial confirm osimertinib plus chemotherapy as the first-line standard of care in EGFR- advanced non-small cell lung cancer,” said study presenter David Planchard, MD, PhD.
The phase 3 trial included 557 adults with previously untreated, EGFR-mutant, locally advanced/metastatic NSCLC, who were randomly assigned to receive osimertinib plus chemotherapy (n=279) or osimertinib alone (n=278).
- The patients received osimertinib at 80 mg per day.
- Baseline characteristics were similar between the arms.
More News
- Major Candy Company Files Chapter 11 Bankruptcy Amid Halloween Week Shock - CCE l ONLINE NEWS
- The Casandra Cascade: Industrialisation Of Fear - FNArena.com
- Football Continues Strong Season, Eyeing Fourth-Straight Little Three Title – The Wesleyan Argus
- Accessible, low-cost biomedical innovations at Tufts’ research lab - The Tufts Daily
- Comment | A spate of dealer anniversaries offers hope amid art market doomerism
- Can MAGA Conservatives and Muslim Americans Unite?
- Santa Cruz Warriors release 2025 training camp roster | NBA G League
- Benz Hui Dies At 76 from Cancer-Related Organ Failure
- Opinion: Get Waymos off our streets - Washington Square News
- Dodgers’ Freddie Freeman ends 18-inning World Series Game 3 thriller